ErbB2/HER2/CD340 human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)

MLN19, HER-2/neu, TKR1, ERBB2, NGL, NEU
En este momento no podemos mostrarle ni los precios ni la disponibilidad

biological source



expressed in HEK 293 cells


≥95% (SDS-PAGE)




5-45 ng/mL

mol wt

calculated mol wt 72.4 kDa
observed mol wt 90-110 kDa (DTT-reduced. Protein migrates due to glycosylation.)


pkg of 10 and 50 μg


<1 EU/μg endotoxin (LAL test)


6-His tagged (C-terminus)

UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... ErbB2(2064)

General description

Human epidermal growth factor receptor 2 (HER2), or erb-b2 receptor tyrosine kinase 2 (ErbB2) or tyrosine kinase receptor-1 (tkr-1), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the epidermal growth factor family of receptor tyrosine kinases (ErbBs). HER2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region and an intracellular tyrosine kinase domain. This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. HER2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.

Biochem/physiol Actions

Human epidermal growth factor receptor 2 (HER2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, overexpression of this protein causes breast cancer. Heterodimer complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of HER2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

Physical form

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.


Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.


NONH for all modes of transport

WGK Germany


Flash Point F

Not applicable

Flash Point C

Not applicable

Certificado de Análisis
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English D P, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)
HER2: biology, detection, and clinical implications.
Gutierrez C and Rachel S
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)
Esteban Cruz et al.
Cancers, 11(6) (2019-06-27)
Nanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor tissues due to tumor-selective accumulation through the enhanced permeability and retention effect (EPR). Gold nanoparticles (AuNP), in particular, possess highly appealing features for development as nanomedicines, such...
The role of p95HER2 in trastuzumab resistance in breast cancer.
Eliyatkin N O, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.